Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy



Status:Completed
Conditions:Diabetic Neuropathy, Neurology
Therapuetic Areas:Endocrinology, Neurology
Healthy:No
Age Range:18 - 75
Updated:1/20/2019
Start Date:June 27, 2017
End Date:November 2, 2018

Use our guide to learn which trials are right for you!

A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multiple-Dose Study to Assess the Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

To evaluate the efficacy of multiple dose levels of NYX-2925 versus placebo in treating the
neuropathic pain associated with Diabetic Peripheral Neuropathy.

This is a randomized, double-blind, parallel-group, placebo-controlled, multiple-dose study
to assess the efficacy and safety of NYX-2925 in subjects with neuropathic pain associated
with diabetic peripheral neuropathy.

The study will be a 6 to 9-week study, including a 1 to 4-week (dependent on duration of
washout period) Screening Period, followed by a 4-week double-blind, randomized,
placebo-controlled Treatment Period, and a 1-week Follow Up Period. Subjects eligible for the
study will randomize to receive either NYX-2925 or placebo for 4 weeks.

Inclusion Criteria:

1. An Institutional Review Board-approved written informed consent and privacy language
(Health Insurance Portability and Accountability Act) authorization must be obtained
from the subject prior to performing any study-related procedures.

2. Subjects who consent to being included in a subject registry database.

3. Male and female subjects ≥18 and ≤75 years of age.

4. Subjects with a diagnosis of Type 2 diabetes.

5. Subjects with a score of ≥4 and ≤9 on the 11-point NRS for average pain intensity over
the past 24 hours at Visit 1.

6. Hemoglobin A1c (HbA1c) ≤11% (measured at Visit 1).

7. Stable use of diabetic medications beginning 1 month prior to Visit 1 (Adequate
glycemic control with only diet and exercise is also permitted.).

8. Subjects with diabetic peripheral neuropathy, of symmetrical nature and in lower
extremities for ≥6 months to ≤10 years, and diagnosed by a score of ≥3 on Michigan
Neuropathy Screening Instrument.

9. Body mass index of <40 kg/m^2

10. Calculated creatinine clearance of ≥60 mL/minute (Cockcroft-Gault formula).

11. Clinical laboratory values must be within normal limits or deemed not clinically
significant by the investigator and sponsor-designated medical monitor.

Inclusion Criteria: Randomization Daily pain scores and diary compliance will be
transferred into the interactive response technology system, which will assess the criteria
for randomization. Subjects whose mean of the daily average pain intensity score during the
preceding 7 (±1) days is within the protocol-defined algorithm and with adequate compliance
with daily diary completion will be eligible for randomization.

Waivers to the inclusion criteria will NOT be allowed.

Exclusion Criteria:

1. Subjects who have a current diagnosis of major psychiatric disorder (including
schizophrenia, bipolar disorder, or panic disorder), including those who have required
an antipsychotic or mood stabilizer (e.g., lithium, carbamazepine, valproate) for a
psychiatric condition in the past year, or subjects who have had a major depressive
episode (MDE) in the past 6 months. Subjects with major depressive disorder (MDD) or
generalized anxiety disorder (GAD) who have been on stable medications for the past 3
months (and are expected to remain stable for the duration of the trial) and whose
condition is currently well-controlled may be included.

2. Subjects who have pain that cannot be clearly differentiated from, or could interfere
with the assessment of peripheral diabetic neuropathy, as measured by the Masquerading
Disorders Tool at Visit 1.

3. Neurologic disorders unrelated to diabetic neuropathy (e.g., phantom limb from
amputation), skin condition in the area of neuropathy that could alter sensation
(e.g., plantar ulcer), or other painful conditions (e.g., arthritis) that, in the
judgment of the investigators, could interfere with reporting of pain due to diabetic
neuropathy.

4. History of hypoglycemia that disturbed consciousness, or ketoacidosis requiring
hospitalization within past 3 months.

5. Subjects with history of severe renal impairment.

6. Impaired hepatic function.

7. Known history of significant cardiovascular condition.

8. History of Huntington's disease, Parkinson's disease, Alzheimer's disease, Multiple
Sclerosis, or a history of seizures, epilepsy, or strokes.

9. HIV infection, hepatitis, or other ongoing infectious disease that the investigator
considers clinically significant.

10. Concomitant use of antiepileptic drugs, non-steroidal anti-inflammatory drugs (except
cardiac preventive acetylsalicylic acid), opioids, muscle relaxants, dextromethorphan
(except low dose intermittent use for cough), tramadol, topical lidocaine, topical
capsaicin, and selective norepinephrine reuptake inhibitors. Subjects are allowed to
enter with a maximum of 1 allowed analgesic medication for neuropathic pain that has
been taken at stable dose for at least 1 month (30 days) prior to Visit 1. Allowed
analgesics may not be N-methyl-D-aspartate receptor ligands, must be non-opioid and
non-sedative and must not interfere with subjects' pain reporting. Tricyclic
antidepressants may be continued if designated as the single analgesic medication for
the treatment of pain.

11. Sensitivity to, allergy to, or concomitant use of N-methyl-D-aspartate receptor
ligands including ketamine, amantadine, dextromethorphan (except low dose intermittent
use for cough), memantine, methadone, dextropropoxyphene, and/or ketobemidone.

12. Amputations of lower extremities (toe amputation is allowed).

13. Any condition, including serious medical conditions that could interfere with the
ability of the subject to participate in the study or could confound study
assessments.

14. Subjects who meet the criteria for suicidal intent, plan and/or behavior by scoring 3
or 4 on Questions 2 or 13, or 2 or higher on any Questions 1a (only if 1b is coded
YES), 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or 14 based on the S-STS (Sheehan - Suicidality
Tracking Scale) at Visit 1 or Visit 2.

Waivers to the exclusion criteria will NOT be allowed.
We found this trial at
32
sites
Austin, Texas 78731
?
mi
from
Austin, TX
Click here to add this to my saved trials
Anaheim, California 92801
?
mi
from
Anaheim, CA
Click here to add this to my saved trials
175 Cross Keys Road
Berlin, New Jersey 08009
?
mi
from
Berlin, NJ
Click here to add this to my saved trials
Bradenton, Florida 34201
?
mi
from
Bradenton, FL
Click here to add this to my saved trials
Brandon, Florida 33511
?
mi
from
Brandon, FL
Click here to add this to my saved trials
Columbus, Georgia 31904
?
mi
from
Columbus, GA
Click here to add this to my saved trials
Dayton, Ohio 45439
?
mi
from
Dayton, OH
Click here to add this to my saved trials
Decatur, Georgia 30033
?
mi
from
Decatur, GA
Click here to add this to my saved trials
Flossmoor, Illinois 60422
?
mi
from
Flossmoor, IL
Click here to add this to my saved trials
13670 Metropolis Avenue
Fort Myers, Florida 33912
?
mi
from
Fort Myers, FL
Click here to add this to my saved trials
Fresno, California 93710
?
mi
from
Fresno, CA
Click here to add this to my saved trials
911 East Hallandale Beach Boulevard
Hallandale Beach, Florida 33009
?
mi
from
Hallandale Beach, FL
Click here to add this to my saved trials
Hazelwood, Missouri 63042
?
mi
from
Hazelwood, MO
Click here to add this to my saved trials
Houston, Texas 77058
?
mi
from
Houston, TX
Click here to add this to my saved trials
Jupiter, Florida 33458
?
mi
from
Jupiter, FL
Click here to add this to my saved trials
Knoxville, Tennessee 37909
?
mi
from
Knoxville, TN
Click here to add this to my saved trials
6401 Poplar Avenue
Memphis, Tennessee 38119
?
mi
from
Memphis, TN
Click here to add this to my saved trials
Meridian, Idaho 83642
?
mi
from
Meridian, ID
Click here to add this to my saved trials
Miami, Florida 33126
?
mi
from
Miami, FL
Click here to add this to my saved trials
New London, Connecticut 06320
?
mi
from
New London, CT
Click here to add this to my saved trials
Norco, California 92860
?
mi
from
Norco, CA
Click here to add this to my saved trials
Norfolk, Virginia 23510
?
mi
from
Norfolk, VA
Click here to add this to my saved trials
10101 West Colonial Drive
Ocoee, Florida 34761
?
mi
from
Ocoee, FL
Click here to add this to my saved trials
Orlando, Florida 32801
?
mi
from
Orlando, FL
Click here to add this to my saved trials
Phoenix, Arizona 85053
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Plano, Texas 75024
?
mi
from
Plano, TX
Click here to add this to my saved trials
500 Helendale Road
Rochester, New York 14618
?
mi
from
Rochester, NY
Click here to add this to my saved trials
Santa Monica, California 90404
?
mi
from
Santa Monica, CA
Click here to add this to my saved trials
5115 North Armenia Avenue
Tampa, Florida 33603
?
mi
from
Tampa, FL
Click here to add this to my saved trials
Tullahoma, Tennessee 37388
?
mi
from
Tullahoma, TN
Click here to add this to my saved trials
Tustin, California 92480
?
mi
from
Tustin, CA
Click here to add this to my saved trials
West Palm Beach, Florida 33401
?
mi
from
West Palm Beach, FL
Click here to add this to my saved trials